Related Experiment Videos

Effect of diltiazem on porcine malignant hyperpyrexia induced by suxamethonium and halothane

P S Foster1, K C Hopkinson, M A Denborough

  • 1Department of Medicine and Clinical Science, John Curtin School of Medical Research, Australian National University, Canberra.

British Journal of Anaesthesia
|May 1, 1989
PubMed

Insights

Diltiazem, a calcium channel antagonist, showed limited effectiveness in preventing or treating porcine malignant hyperpyrexia (MH). It is not recommended as a primary treatment for MH, with dantrolene remaining the preferred therapeutic agent.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Veterinary Medicine

Background:

  • Malignant hyperpyrexia (MH) is a severe hypermetabolic state triggered by certain anesthetic agents.
  • Porcine models are crucial for studying MH pathophysiology and therapeutic interventions.

Purpose of the Study:

  • To investigate the efficacy of diltiazem, a calcium channel antagonist, in inhibiting and reversing malignant hyperpyrexia in pigs.
  • To compare diltiazem's therapeutic potential against established MH treatments.

Main Methods:

  • Porcine subjects were utilized to model malignant hyperpyrexia.
  • Diltiazem was administered as both a pretreatment and a treatment for induced MH episodes.

Main Results:

  • Pretreatment with diltiazem partially modified the MH response.
  • Diltiazem demonstrated only partial effectiveness in treating mild or early-stage MH.
  • Diltiazem did not effectively reverse established MH symptoms.

Conclusions:

  • Diltiazem is not an effective therapeutic agent for managing malignant hyperpyrexia.
  • Dantrolene remains the gold standard treatment for MH and should not be replaced by diltiazem.

Related Concept Videos